Adalimumab-adbm Subcutaneous and Denosumab Injection (Xgeva)
Determining the interaction of Adalimumab-adbm Subcutaneous and Denosumab Injection (Xgeva) and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using denosumab together with adalimumab can increase the risk of serious infections involving the skin, lower stomach area (abdomen), bladder, ear, or inner lining of the heart. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. Contact your doctor immediately if you develop fever or chills; red, swollen skin or skin that is hot or tender to the touch; itching or rash; blisters; severe abdominal pain; or frequent, urgent, or painful/burning urination. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Concomitant use of immunosuppressive or myelosuppressive agents with denosumab may increase the risk of serious infections. Denosumab binds to and inhibits the receptor activator of nuclear factor kappa-B ligand (RANKL), which is expressed on activated T and B lymphocytes and in lymph nodes. Thus, denosumab alone may increase the risk of infections. In a clinical trial of over 7800 women with postmenopausal osteoporosis, the incidence of nonfatal serious infections was 3.3% in the placebo group and 4.0% in the denosumab group. Specifically, hospitalizations due to skin infections including erysipelas and cellulitis (
- "Product Information. Prolia (denosumab)." Amgen USA, Thousand Oaks, CA.
Generic Name: adalimumab
Brand name: Humira, Humira Pen, Humira Pen Crohns/UlcerColit/HidraSuppur, Humira Pen Psoriasis/Uveitis Starter Package, Humira Pediatric, Humira Pediatric Crohn's Disease Starter Pack, Humira Pre-Filled Syringe, Humira Pen Psoriasis/Uveitis/Adol HidraSuppur Starter Pack, Humira Pen Crohns/Ulcer Colitis/Hidradenitis Suppurati StrPk
Synonyms: Adalimumab
Generic Name: denosumab
Brand name: Prolia, Xgeva
Synonyms: Denosumab
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Adalimumab-adbm Subcutaneous-Denosumab Subcutaneous
- Adalimumab-adbm Subcutaneous-Denovo
- Adalimumab-adbm Subcutaneous-Dent-O-Kain/20
- Adalimumab-adbm Subcutaneous-Denti-Care Denti-Freeze Topical Anesthetic
- Adalimumab-adbm Subcutaneous-DentiPatch
- Adalimumab-adbm Subcutaneous-Deoxycholic acid
- Denosumab Injection (Xgeva)-Adalimumab-atto Subcutaneous
- Denosumab Injection (Xgeva)-Adapalene
- Denosumab Injection (Xgeva)-Adapalene and Benzoyl Peroxide
- Denosumab Injection (Xgeva)-Adapalene and Benzoyl Peroxide Gel
- Denosumab Injection (Xgeva)-Adapalene and benzoyl peroxide topical
- Denosumab Injection (Xgeva)-Adapalene and benzoyl peroxide Topical application